How are people with long COVID faring two years after their initial infection? Many have recovered. Some still struggle with symptoms – this is more likely for those who were initially hospitalised.
We still have much to learn about many aspects of COVID-19 — including its lingering health effects and the mechanics of its endless mutations — but we do know one thing: we can’t let our guard down.
The challenges facing South African judges have been well documented for decades. They include the high number of unfilled vacancies and poor working conditions.
With COVID boosters expected to cost £100 when they go on sale in UK pharmacies, there are concerns about whether this will put people off getting the jab.
More than half our interviewees described feelings of profound anguish as long COVID forced them to doubt their identity and question their life purpose
As COVID finds its equilibrium, infection rates will rise and fall, influenced by seasons, school holidays and new subvariants. Managing the risk is complex and needs to be cost effective.
Models are powerful, but they have their risks, and AI is just the latest example. The best way to address this is by ensuring that AI can be developed in a globally decentralized way.
In-person collaboration between Indigenous communities has been aided by information technologies like Zoom. However, recent attempts to mine personal data raise concerns about data ownership.
Two economists calculated that the Paycheck Protection Program saved more than 450,000 nonprofit jobs in the first six months after the pandemic was declared.
The World Health Organization has classified the EG.5 family of Omicron variants, including Eris, as ‘variants of interest’. What does that mean? And how does Eris differ to other Omicron variants?
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand